European Antibody Congress

 

2-5 November 2020 | Live Digital

 

 

000s
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
3
Co-located events

Sessions you can't miss

Human monoclonal antibodies for emerging infections

•Single cell technologies for isolation of human mAbs to viruses. • Molecular basis for high potency neutralization of viruses
•Molecular basis of synergistic combinations of mAbs
• Envision the future landscape for ADC’s

James Crowe, Professor, Pediatrics and Pathology, Microbiology and Immunology, Director, Vanderbilt Vaccine Center

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

• Isolation of 403 monoclonal antibodies from COVID-19 patients yielded 19 potently neutralizing antibodies against SARS-CoV-2
• The SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes

Marit van Gils , Associate Professor , University of Amsterdam

Antibody drug conjugates for cancer therapy: where we are and what lies ahead?

• In the last year, four ADCs have been approved for cancer therapy, and many others are in advanced-stage clinical trials
• Isolation of 403 monoclonal antibodies from COVID-19 patients yielded 19 potently neutralizing antibodies against SARS-CoV-2
• An overview of the field will be provided and the challenges that lie ahead will be discussed

Peter Senter , VP, Distinguished Research Fellow , Seattle Genetics

Festibval of Biologics

 

There are two parts to the Festival of Biologics: three conferences covering Antibodies, Immunotherapy, Biosimilars and an exhibition featuring solutions for pharma and biotech.